A Phase III Randomized Double-Blind Study of Adjuvant STI571 (Gleevec TM) versus Placebo in Patients Following the Resection of Primary Gastrointestinal Stromal Tumor (GIST)

Closed

Phase

Published

Abbreviated Title

Primary GIST

Activated

10/01/2002

Closed

02/09/2007

Participants

CTSU

Research committees

Sarcoma

Treatment

STI-571/Imatinib Surgery

Eligibility Criteria Expand/Collapse

The Southwest Oncology Group participated in this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute.

Please contact the CTSU directly by either phone (1-888-823-5923) or on the CTSU web site (http://www.ctsu.org/) for information.

Publication Information Expand/Collapse

2014

Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial

C Corless;K Ballman;C Antonescu;V Kolesnikova;R Maki;P Pisters;M Blackstein;C Blanke;G Demetri;MC Heinrich;M von Mehren;S Patel;M McCarter;K Owzar;R Dematteo Journal of Clinical Oncology 32(15):1563-1570;

PMid: PMID24638003 | PMC number: PMC4026579